189 related articles for article (PubMed ID: 28345929)
1. Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions.
Ly JQ; Messick K; Qin A; Takahashi RH; Choo EF
Mol Pharm; 2017 May; 14(5):1754-1759. PubMed ID: 28345929
[TBL] [Abstract][Full Text] [Related]
2. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
[TBL] [Abstract][Full Text] [Related]
3. Investigating the Utility of Humanized Pregnane X Receptor-Constitutive Androstane Receptor-CYP3A4/7 Mouse Model to Assess CYP3A-Mediated Induction.
Ly JQ; Wong S; Liu L; Li R; Messick K; Chang JH
Drug Metab Dispos; 2021 Jul; 49(7):540-547. PubMed ID: 33863817
[TBL] [Abstract][Full Text] [Related]
4. Rifampin-Mediated Induction of Tamoxifen Metabolism in a Humanized PXR-CAR-CYP3A4/3A7-CYP2D6 Mouse Model.
Chang JH; Chen J; Liu L; Messick K; Ly J
Drug Metab Dispos; 2016 Nov; 44(11):1736-1741. PubMed ID: 27538915
[TBL] [Abstract][Full Text] [Related]
5. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
[TBL] [Abstract][Full Text] [Related]
6. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
7. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.
Ohno Y; Hisaka A; Ueno M; Suzuki H
Clin Pharmacokinet; 2008; 47(10):669-80. PubMed ID: 18783297
[TBL] [Abstract][Full Text] [Related]
8. A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4.
Ma X; Cheung C; Krausz KW; Shah YM; Wang T; Idle JR; Gonzalez FJ
Drug Metab Dispos; 2008 Dec; 36(12):2506-12. PubMed ID: 18799805
[TBL] [Abstract][Full Text] [Related]
9. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
Ohno Y; Hisaka A; Suzuki H
Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
[TBL] [Abstract][Full Text] [Related]
10. Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver.
Hasegawa M; Tahara H; Inoue R; Kakuni M; Tateno C; Ushiki J
Drug Metab Dispos; 2012 Mar; 40(3):474-80. PubMed ID: 22126990
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Martin P; Oliver S; Robertson J; Kennedy SJ; Read J; Duvauchelle T
Drugs R D; 2011; 11(1):37-51. PubMed ID: 21410294
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.
Yamazaki S; Johnson TR; Smith BJ
Drug Metab Dispos; 2015 Oct; 43(10):1417-29. PubMed ID: 26180127
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
15. Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
Yamazaki S; Loi CM; Kimoto E; Costales C; Varma MV
Drug Metab Dispos; 2018 Aug; 46(8):1200-1211. PubMed ID: 29739809
[TBL] [Abstract][Full Text] [Related]
16. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
17. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.
Salerno SN; CarreƱo FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D
Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994
[TBL] [Abstract][Full Text] [Related]
18. CYP3A4 Induction in the Liver and Intestine of Pregnane X Receptor/CYP3A-Humanized Mice: Approaches by Mass Spectrometry Imaging and Portal Blood Analysis.
Kobayashi K; Kuze J; Abe S; Takehara S; Minegishi G; Igarashi K; Kitajima S; Kanno J; Yamamoto T; Oshimura M; Kazuki Y
Mol Pharmacol; 2019 Nov; 96(5):600-608. PubMed ID: 31455676
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.
de Zwart L; Snoeys J; De Jong J; Sukbuntherng J; Mannaert E; Monshouwer M
Clin Pharmacol Ther; 2016 Nov; 100(5):548-557. PubMed ID: 27367453
[TBL] [Abstract][Full Text] [Related]
20. Modulation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation by ursolic acid (UA) attenuates rifampin-isoniazid cytotoxicity.
Chang HY; Chen CJ; Ma WC; Cheng WK; Lin YN; Lee YR; Chen JJ; Lim YP
Phytomedicine; 2017 Dec; 36():37-49. PubMed ID: 29157826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]